X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 9,480,000 shares, a drop of 14.3% from the February 13th total of 11,060,000 shares. Based on an average trading volume of 4,100,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 5.7% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

Insider Activity at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 74,773 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Paula Ragan sold 76,473 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company's stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 in the last 90 days. 1.62% of the stock is owned by corporate insiders.

Remove Ads

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. State Street Corp raised its position in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company's stock worth $1,976,000 after acquiring an additional 189,105 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $30,000. XTX Topco Ltd raised its position in shares of X4 Pharmaceuticals by 41.7% in the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after acquiring an additional 46,397 shares in the last quarter. SG Americas Securities LLC raised its position in shares of X4 Pharmaceuticals by 233.0% in the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock worth $134,000 after acquiring an additional 128,148 shares in the last quarter. Finally, Atria Wealth Solutions Inc. bought a new stake in X4 Pharmaceuticals in the 4th quarter valued at about $44,000. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Trading Up 1.0 %

Shares of XFOR stock traded up $0.00 during mid-day trading on Friday, hitting $0.31. The company's stock had a trading volume of 1,301,075 shares, compared to its average volume of 2,903,791. The company's fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.53. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89. The company has a market cap of $52.41 million, a PE ratio of -3.41 and a beta of 0.39.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.